Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.

Novo Nordisk A/S97 enrolled

Overview

This trial is conducted in Asia. The aim of the trial is to compare the glycaemic control of Insulin glargine versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in combination with metformin in subjects with Type 2 Diabetes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

biphasic insulin aspartDRUG

insulin glargineDRUG

metforminDRUG

Eligibility

Sex: ALLMin age: 35 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetes * Body mass index equal to or lesser than 35.0 kg/m2 * Currently treated with oral hypoglycaemic drug Exclusion Criteria: * Known hypoglycaemia unawareness or recurrent major hypoglycaemia as judged by the Investigator * Any condition that the Investigator and/or the Sponsor feel would interfere with trial participation or evaluation of results

Locations (1)

Novo Nordisk Investigational Site

Istanbul, Turkey (Türkiye)

Outcomes

Primary Outcomes

HbA1c

Time frame: Measured at end of treatment (26 weeks)

Secondary Outcomes

safety variables

other glycemic variables

Fasting plasma glucose value

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.